Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766921 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,393
- Enrollment target
NCT01766921: Completed Phase 2 study, sponsored by Novartis Vaccines.
NCT01766921 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 1,393 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (947% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01766921, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,393 participants
- Enrollment target
Study Summary
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
Primary Outcome
The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion. The CBER criterion for the elderly population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or
Interventions
- BIOLOGICAL Adjuvanted H5N1 pandemic influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,393 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT01766921 record still lists
NCT01766921 is an interventional study that assigns participants to a tested intervention. Its 1,393 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (947% higher).
The record links to 0 conditions, and to 1 intervention - of which Adjuvanted H5N1 pandemic influenza vaccine is the first listed.
NCT01766921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01766921 about?
NCT01766921 is a clinical study titled "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects". Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
What is the current status of trial NCT01766921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,393 participants. The study started on 2013-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01766921?
The interventions under investigation include: Adjuvanted H5N1 pandemic influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01766921?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01766921's enrollment target sits among peer trials
1,393 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia